CClinicalTrials.gg
Sign In
CompletedNCT01493362Updated Aug 15, 2014

Imaging the Dopamine Systems in Bulimia Nervosa

An observational study in Eating Disorders, sponsored by New York State Psychiatric Institute. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-15.

Sponsored by New York State Psychiatric Institute · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
33
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

This study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.

02

Conditions studied

  • Eating Disorders

Keywords

  • Bulimia Nervosa
  • PET Imaging
  • Dopamine
03

In context

Bulimia

319 studies on the registry are indexed under Bulimia; 53 are open to participants now.

This study's enrollment of 33 is below the median of 76 across 58 observational studies indexed under Bulimia.

Browse Bulimia studies →

Lead sponsor

New York State Psychiatric Institute is the lead sponsor of 425 studies on the registry; 26 are open to participants now.

Of its 50 completed or terminated interventional studies of FDA-regulated products, 45 (90%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will include people with bulimia nervosa seeking inpatient or outpatient treatment and people who will act as healthy control participants

Inclusion criteria

Participants with BN:

  • Meets DSM-IV criteria for BN
  • Sufficiently medically and psychiatrically stable to participate in research

Health Control Participants:

  • No current or past psychiatric illness
  • Between 80% and 120% of ideal body weight

Exclusion criteria

Exclusion Criteria:

All participants:

  • Current use of psychotropic medication such as anti psychotics or antidepressants
  • Pregnant or breastfeeding
  • history of substance abuse
  • Significant medical illness
  • High blood pressure (resting systolic blood pressure greater than 150mmHg and diastolic blood pressure greater that 90 mmHg)
  • Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV
  • Metal implants or paramagnetic objects contained within the body that may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines
  • Exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry
  • Previous adverse reaction to psycho stimulants
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
33 participants (actual)
Patient registry
No

Groups and cohorts

  • 1

    Participants with Bulimia Nervosa

  • 2

    Participants who are healthy controls

06

What researchers measure

Primary outcomes

  1. D2 receptor density

    Time frame: Measured at baseline

  2. DA release in the striatum

    Time frame: Measures after Mythlyphenidate challenge

07

Study locations

1 site
  • New York State Psychiatric Institute
    New York, New York 10032, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01493362
Lead sponsor
New York State Psychiatric Institute
Collaborators
National Institute of Mental Health (NIMH)
Responsible party
Sponsor
First posted
Dec 16, 2011
Start date
Jan 2008
Primary completion
Dec 2013
Completion
Dec 2013
Last update
Aug 15, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Bulimia→

Other studies from this sponsor

New York State Psychiatric Institute

Start the discussion